- Home
- ALKT vs CELC Comparison
ALKT vs CELC Comparison
Compare ALKT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- CELC
- Stock Information
- Founded
- ALKT 2007
- CELC 2011
- Country
- ALKT United States
- CELC United States
- Employees
- ALKT N/A
- CELC N/A
- Industry
- ALKT EDP Services
- CELC Medical Specialities
- Sector
- ALKT Technology
- CELC Health Care
- Exchange
- ALKT Nasdaq
- CELC Nasdaq
- Market Cap
- ALKT 2.6B
- CELC 3.1B
- IPO Year
- ALKT 2021
- CELC 2017
- Fundamental
- Price
- ALKT $20.29
- CELC $77.16
- Analyst Decision
- ALKT Buy
- CELC Strong Buy
- Analyst Count
- ALKT 8
- CELC 5
- Target Price
- ALKT $36.63
- CELC $69.40
- AVG Volume (30 Days)
- ALKT 1.2M
- CELC 1.5M
- Earning Date
- ALKT 10-30-2025
- CELC 11-14-2025
- Dividend Yield
- ALKT N/A
- CELC N/A
- EPS Growth
- ALKT N/A
- CELC N/A
- EPS
- ALKT N/A
- CELC N/A
- Revenue
- ALKT $412,504,000.00
- CELC N/A
- Revenue This Year
- ALKT $35.94
- CELC N/A
- Revenue Next Year
- ALKT $24.65
- CELC N/A
- P/E Ratio
- ALKT N/A
- CELC N/A
- Revenue Growth
- ALKT 30.72
- CELC N/A
- 52 Week Low
- ALKT $19.28
- CELC $7.58
- 52 Week High
- ALKT $42.29
- CELC $83.00
- Technical
- Relative Strength Index (RSI)
- ALKT 28.27
- CELC 69.95
- Support Level
- ALKT $23.02
- CELC $71.61
- Resistance Level
- ALKT $24.12
- CELC $80.13
- Average True Range (ATR)
- ALKT 0.90
- CELC 5.17
- MACD
- ALKT -0.19
- CELC 1.75
- Stochastic Oscillator
- ALKT 20.87
- CELC 84.57
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.